{
    "organizations": [],
    "uuid": "623ad4e0cad33875031255cb84533337e2fa0bc7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-medicinova-posts-results-of-phase/brief-medicinova-posts-results-of-phase-2-clinical-trial-of-mn-166-in-methamphetamine-dependence-idUSASC09U5J",
    "ord_in_thread": 0,
    "title": "BRIEF-MediciNova Posts Results Of Phase 2 Clinical Trial Of MN-166 In Methamphetamine Dependence",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29 (Reuters) - MediciNova Inc:\n* MEDICINOVA ANNOUNCES RESULTS OF PHASE 2 CLINICAL TRIAL OF MN-166 (IBUDILAST) IN METHAMPHETAMINE DEPENDENCE\n* MEDICINOVA INC - ‍DID NOT MEET PRIMARY ENDPOINT OF METHAMPHETAMINE ABSTINENCE CONFIRMED VIA URINE DRUG SCREENS DURING FINAL TWO WEEKS OF TREATMENT​\n* MEDICINOVA INC - ‍MN-166 (IBUDILAST) DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE​\n* MEDICINOVA INC - ‍THERE WAS NOT AN INCREASED RATE OF SERIOUS OR SEVERE ADVERSE EVENTS IN MN-166 (IBUDILAST) GROUP COMPARED TO PLACEBO GROUP​\n* MEDICINOVA INC SAYS THERE WERE NO INFECTIONS, NO CANCERS, NO CARDIOVASCULAR EVENTS NO DEATHS RELATED TO MN-166\n* MEDICINOVA - COMMON TREATMENT-RELATED ADVERSE EVENTS DURING STUDY WERE GASTROINTESTINAL ADVERSE EVENTS, OCCURRED WITH HIGHER FREQUENCY IN MN-166 GROUP​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-29T19:56:00.000+03:00",
    "crawled": "2018-03-29T15:02:48.107+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "medicinova",
        "inc",
        "medicinova",
        "announces",
        "result",
        "phase",
        "clinical",
        "trial",
        "ibudilast",
        "methamphetamine",
        "dependence",
        "medicinova",
        "inc",
        "meet",
        "primary",
        "endpoint",
        "methamphetamine",
        "abstinence",
        "confirmed",
        "via",
        "urine",
        "drug",
        "screen",
        "final",
        "two",
        "week",
        "medicinova",
        "inc",
        "ibudilast",
        "demonstrated",
        "favorable",
        "safety",
        "tolerability",
        "medicinova",
        "inc",
        "increased",
        "rate",
        "serious",
        "severe",
        "adverse",
        "event",
        "ibudilast",
        "group",
        "compared",
        "placebo",
        "medicinova",
        "inc",
        "say",
        "infection",
        "cancer",
        "cardiovascular",
        "event",
        "death",
        "related",
        "medicinova",
        "common",
        "adverse",
        "event",
        "study",
        "gastrointestinal",
        "adverse",
        "event",
        "occurred",
        "higher",
        "frequency",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}